Is Aelis Farma SA halal to invest in?

According to Musaffa's Shariah screening methodology, Aelis Farma SA (AELIS.PA) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Aelis Farma SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Aelis Farma SA using these criteria to determine its compliance status.

Can Muslims buy shares of Aelis Farma SA?

Muslim investors may consider investing in Aelis Farma SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Aelis Farma SA classified as NOT HALAL?

Musaffa determines the Shariah status of Aelis Farma SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Aelis Farma SA updated?

The Shariah compliance status of Aelis Farma SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Aelis Farma SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Aelis Farma SA?

You can check the latest Shariah compliance status of Aelis Farma SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Aelis Farma SA AELIS.PA

€1.22

Last Updated: May 15, 12:00 AM·XPAR

AELIS.PA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: July 25, 2025

Report Source: 2024 Annual Report

Analyst's Ratings for Aelis Farma SA (AELIS.PA)

Based on 9 analysts giving stock ratings to Aelis Farma SA in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Aelis Farma SA. Stock Analysis AELIS.PA

France Health Care Nano Cap Report: 2024 Annual

Aelis Farma SA is a biopharmaceutical company. The firm provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). The company offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. The company provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The firm operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.

Key Statistics of Aelis Farma SA (AELIS.PA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€1.22€1.22

Today's Open

€1.22

Volume

74.00

P/E Ratio (TTM)

52 Week Range

€0.67€2.30

Market Cap

17.41M

Avg. Volume

17.42K

Dividend Yield

Financial Metrics & Statements of Aelis Farma SA (AELIS.PA)

FAQ's for Aelis Farma SA (AELIS.PA)

According to Musaffa’s Shariah screening methodology, Aelis Farma SA (AELIS.PA) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.